Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Construction In Progress: HK$2.56 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) Construction In Progress?

Alebund Pharmaceuticals (Jiangsu) HKSE:09637 -2.87% 5 Construction In Progress is HK$2.56 Mil as of Dec. 2025. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review.

Alebund Pharmaceuticals (Jiangsu)'s quarterly construction in progress increased from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$5.94 Mil) but then declined from Dec. 2024 (HK$5.94 Mil) to Dec. 2025 (HK$2.56 Mil).

Alebund Pharmaceuticals (Jiangsu)'s annual construction in progress increased from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$5.94 Mil) but then declined from Dec. 2024 (HK$5.94 Mil) to Dec. 2025 (HK$2.56 Mil).

Alebund Pharmaceuticals (Jiangsu) Construction In Progress Historical Data

* Premium members only.

The historical data trend for Alebund Pharmaceuticals (Jiangsu)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alebund Pharmaceuticals (Jiangsu) Construction In Progress Chart

Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend Dec24 Dec25
Construction In Progress
5.94 2.56

Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24 Dec25
Construction In Progress 5.94 2.56
HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$2.56 Mil mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Construction In Progress of HK$2.56 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s Construction In Progress too high?
Alebund Pharmaceuticals (Jiangsu)'s current Construction In Progress is HK$2.56 Mil. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Construction In Progress compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s Construction In Progress of HK$2.56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current Construction In Progress is HK$2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Construction In Progress of HK$2.56 Mil. The current Construction In Progress is HK$2.56 Mil. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Construction In Progress is HK$2.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price